Loading...
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
    • Ownership Structure
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Nomination Committee
      • Nomination Committees
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Press Releases

Press Releases
    • Regulatory
    • All releases
2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
May 18, 2022
Non Regulatory

Synact Pharma to present at the ABGSC Life Science Summit

May 4, 2022
Non Regulatory

SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet

April 1, 2022
Non Regulatory

SynAct publishes prospectus in connection with a fully guaranteed rights issue

January 7, 2022
Non Regulatory

SynAct Pharma appoints Patrik Renblad as CFO

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe

Type of information
Language
Read more about how we protect your personal data.